InflaRx N.V. (IFRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IFRX Profit Margin, ROE & Profitability Analysis
IFRX vs Healthcare Sector: How InflaRx N.V. Compares
How InflaRx N.V. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is InflaRx N.V. Stock Overvalued? IFRX Valuation Analysis 2026
Based on fundamental analysis, InflaRx N.V. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
InflaRx N.V. Balance Sheet: IFRX Debt, Cash & Liquidity
IFRX Revenue Growth, EPS Growth & YoY Performance
IFRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for InflaRx N.V. (CIK: 0001708688)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IFRX
What is the AI rating for IFRX?
InflaRx N.V. (IFRX) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IFRX's key strengths?
Claude: Analysis in progress.
What are the risks of investing in IFRX?
Claude: Analysis in progress.
What is IFRX's revenue and growth?
InflaRx N.V. reported revenue of N/A.
Does IFRX pay dividends?
InflaRx N.V. does not currently pay dividends.
Where can I find IFRX SEC filings?
Official SEC filings for InflaRx N.V. (CIK: 0001708688) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IFRX's EPS?
InflaRx N.V. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IFRX's fundamental grade?
Based on our AI fundamental analysis in May 2026, InflaRx N.V. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IFRX stock overvalued or undervalued?
Valuation metrics for IFRX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IFRX's AI grade for 2026?
Our dual AI analysis gives InflaRx N.V. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IFRX's free cash flow?
InflaRx N.V.'s operating cash flow is N/A, with capital expenditures of N/A.
How does IFRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).